AbbVie Inc. (ABBV) EBITDA
The ebitda for AbbVie Inc. (ABBV) is $17.63 Billion with a year-over-year change of +18.24%. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) measures a company's operating performance by removing non-cash charges and capital structure effects.
ABBV EBITDA Chart
Current EBITDA
$17.63B
$17.63 Billion
Year-over-Year Change
+18.24%
vs. $14.91B prior year
Historical Data
17
Years of data available
Annual EBITDA History
| Year | EBITDA | YoY Change | % Change |
|---|---|---|---|
| 2025 | $17.63B | +$2.72B | +18.24% |
| 2024 | $14.91B | $-2.26B | -13.17% |
| 2023 | $17.17B | $-7.00B | -28.97% |
| 2022 | $24.17B | +$241.00M | +1.01% |
| 2021 | $23.93B | +$11.61B | +94.21% |
| 2020 | $12.32B | +$96.00M | +0.79% |
| 2019 | $12.23B | +$3.92B | +47.14% |
| 2018 | $8.31B | $-2.07B | -19.93% |
| 2017 | $10.38B | +$258.00M | +2.55% |
| 2016 | $10.12B | +$1.92B | +23.41% |
| 2015 | $8.20B | +$4.62B | +128.79% |
| 2014 | $3.58B | $-2.94B | -45.10% |
| 2013 | $6.53B | $-451.00M | -6.46% |
| 2012 | $6.98B | +$2.04B | +41.28% |
| 2011 | $4.94B | $-1.08B | -17.94% |
| 2010 | $6.02B | +$220.71M | +3.81% |
| 2009 | $5.80B | — | — |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael